Global Thymus Cancer Market - 2023-2030

Global Thymus Cancer Market - 2023-2030

The global thymus cancer market reached US$ 461.4 million in 2022 and is projected to witness to reach up to US$ 702.5 million by 2030. The thymus cancer market is expected to exhibit a CAGR of 5.5% during the forecast period (2023-2030). The key players are adopting strategies such as partnerships, mergers, acquisitions, product approvals, and regional expansion to stand out as strong competitors in the thymus cancer market.

For instance, on January 17, 2023, for adult patients with stage IB (T2a 4 cm), stage II, or stage IIIA non-small cell lung cancer, Merck's anti-PD-1 medication, KEYTRUDA, was approved by the U.S. Food and Drug Administration (FDA) as a single agent for adjuvant treatment after surgical resection and platinum-based chemotherapy (NSCLC).

Thymus cancer is a disease in which malignant (cancer) cells form in the thymus. Thymoma, Thymic Carcinoma, and Thymic Neuroendocrine Tumor (TNET) also called thymic epithelial tumors (TETs), are types of rare cancers that can form in the cells covering the thymus’s outside surface. The increasing market developments, growing cases of thymus cancer, and increasing research activities are some of the factors that are expected to drive the global thymus cancer market growth over the forecast period.

Market Dynamics

The increasing cases of thymus cancer are driving the thymus cancer market growth

The increasing prevalence of thymus cancer is expected to boost the market growth. For instance, according to Cancer Research UK, thymus gland cancer is rare. In the U.K., around 345 people are diagnosed with thymus cancer each year. This includes thymoma and thymic carcinoma.

However, the exact number is not known and may be higher than the estimated number that can be detected using computed tomography scans. Thymoma and thymic carcinoma usually occurs in people between the ages of 40 and 60 but can occur at almost any age. Thus, the rising older population is likely to contribute to thymus cancer prevalence.

The growing research activities provide the market with growth opportunities

There are several approaches that could be pursued to develop new treatments for thymus cancer presenting the thymus cancer market with lucrative growth opportunities in the forthcoming years. For example, researchers are exploring the use of immunotherapies, which harness the power of the immune system to target and destroy cancer cells. Other potential approaches include targeted therapies that focus on specific molecular pathways involved in the development and progression of thymus cancer.

COVID-19 Impact Analysis

The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with pricing dynamics (including pricing change during and post-pandemic comparing it to pre-COVID scenarios), demand-supply spectrum (shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), government initiatives (initiatives to revive market, sector or industry by government bodies) and manufacturers strategic initiatives (what manufacturers did to mitigate the COVID issues will be covered here).

Russia-Ukraine Conflict Analysis

The Russia-Ukraine war is estimated to have nearly negligible impact on the global thymus cancer market, owing to the absence of key market players in this region and the overall low prevalence of the condition. Still, the war has slowed the research activities carried out in this region, which is expected to have the slightest impact on the global thymus cancer market.

Global Recession Impact Analysis

The healthcare industry is not completely immune to recession, as healthcare institutions thought firings and employing freezes during past financial downturns. That stated, the industry does cope finer than other sectors because of its essential nature. The recession has led to a decrease in research investments which has negatively impacted the market growth in the past few years.

Artificial Intelligence Impact Analysis

The application of AI in different cancers is disproportionate, and enough attention has not been paid to mediastinal tumors, showing a huge gap and potential for future development. For instance, the researchers from the Department of Radiology, Shantou Central Hospital concluded that the machine learning-based CT image had significant values in the prediction of different histological classifications and even invasion levels from their investigation. Thus, artificial intelligence is estimated to positively impact the global thymus cancer market in the upcoming years.

For more details on this report - Request for Sample

Segment Analysis

The global thymus cancer market is segmented based on cancer type, treatment, end users, and region.

The surgical treatment segment is estimated to hold 39.3% of the total market by 2030

Surgical removal of the tumor is the primary form of treatment for thymus cancer. An incision is made in the center of the chest and the sternum (chest bone) is split, allowing the surgeon full access to the thymus gland. Depending on the extent of cancer, the tumor is removed and the entire thymus gland is removed (a procedure called a thymectomy), and/or parts of nearby organs where the tumor has spread. Moreover, the rising clinical research activities are boosting the surgery treatment segment growth in the forecast period.

For instance, in 2022, according to ClinicalTrials.com., Shanghai Zhongshan Hospital completed an interventional study comparing the safety and perioperative outcomes of the subxiphoid approach versus lateral intercostal approach thoracoscopic thymectomy for Masaoka-Koga I-II Thymoma.

Geographical Analysis

Europe is estimated to hold the second-largest share of the global thymus cancer market during the forecast period

The increasing initiatives and funding in the fight against thymus cancer in this region are boosting the European thymus cancer market growth and are estimated to hold around 26.2% of the global thymus cancer market by 2030. For instance, ThymicUK, a registered charity established by patients with thymic cancers, their carers, and families and friends, raised slightly more than £10,000 from fundraisers and grants to support those impacted by rare thymic cancers.

Competitive Landscape

The major global players in the market include Merck & Co., Inc., Viatris Inc., F. Hoffmann-La Roche Ltd, Elekta AB, Asensus Surgical US, Inc., Pfizer Inc., Getwell Pharmaceuticals, Bristol-Myers Squibb Company, Intuitive Surgical and Varian Medical Systems, Inc. (Siemens Healthineers AG) among others.

Why Purchase the Report?
• To visualize the global thymus cancer market segmentation based on product, application, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of thymus cancer market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global thymus cancer market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies